

Appl. No. : 10/006,867
Filed : December 6, 2001

AMENDMENTS TO THE CLAIMS

1-43. (Cancelled)

44. (Previously presented) An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:2;
- (b) the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO:2; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099,

wherein said extracellular domain is selected from the group consisting of amino acids 34-53, 114-121, and 181-266 of SEQ ID NO:2.

45. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide of SEQ ID NO:2.

46. (Cancelled)

47. (Currently amended) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO:2, wherein said extracellular domain is selected from the group consisting of amino acids 34-53, 114-121, and 181-266 of SEQ ID NO:2.

48. (Cancelled)

49. (Previously presented) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099.

50. (Currently amended) A chimeric polypeptide comprising a polypeptide according to ~~Claim 42~~ Claim 44 fused to a heterologous polypeptide.

51. (Previously presented) The chimeric polypeptide of Claim 50, wherein the heterologous polypeptide is a tag polypeptide or an Fc region of an immunoglobulin.

52. (Previously presented) An isolated polypeptide having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide of SEQ ID NO:2;

Appl. No. : **10/006,867**
Filed : **December 6, 2001**

(b) the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO:2; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099,

wherein said extracellular domain is selected from the group consisting of amino acids 34-53, 114-121, and 181-266 of SEQ ID NO:2; and

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO:2 in rectal or lung tissue samples.

53. (Previously presented) The isolated polypeptide of Claim 52 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO:2;

(b) the amino acid sequence of the extracellular domain of the polypeptide of SEQ ID NO:2; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203099,

wherein said extracellular domain is selected from the group consisting of amino acids 34-53, 114-121, and 181-266 of SEQ ID NO:2; and

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO:2 in rectal or lung tissue samples.

54. (Previously presented) A chimeric polypeptide comprising a polypeptide according to Claim 52 fused to a heterologous polypeptide.

55. (Previously presented) The chimeric polypeptide of Claim 54, wherein said heterologous polypeptide is a tag polypeptide or an Fc region of an immunoglobulin.